The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,116.00
Bid: 12,114.00
Ask: 12,118.00
Change: 92.00 (0.77%)
Spread: 4.00 (0.033%)
Open: 11,950.00
High: 12,142.00
Low: 11,944.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Cabinet minister warns of "concerning situation" as Omicron spreads

Sat, 11th Dec 2021 09:29

(Alliance News) - A booster dose sees the risk of symptomatic infection with the Omicron variant "significantly reduced", according to health officials who have urged all those eligible to make sure they get their third jab.

It comes as the experts warned the new variant could become the dominant strain in the UK by mid-December, with a Cabinet minister saying everything is being kept "under review" in terms of measures to tackle the spread.

Analysis by the UK Health Security Agency found that the AstraZeneca PLC and Pfizer Inc-BioNTech SE vaccines provided "much lower" levels of protection against symptomatic infection with Omicron compared to Delta.

But the preliminary data, which looked at 581 people with confirmed Omicron, suggested effectiveness seemed to "increase considerably" in the early period after a booster dose, giving around 70% to 75% protection against symptomatic infection.

The findings come as daily Covid-19 cases reached their highest level in almost a year and the UKHSA predicted that, if current trends continue, the UK will exceed one million infections by the end of the month.

Cabinet minister Michael Gove warned of a "deeply concerning situation" after holding a Cobra meeting on Friday afternoon to discuss the latest data and the co-ordinated response across the four nations.

The government said, as of 9 am on Friday, there had been a further 58,194 lab-confirmed Covid-19 cases in the UK.

The last time a higher daily figure was reported was on January 9, when 59,937 cases were recorded.

An additional 448 confirmed cases of the Omicron variant have been reported across the UK, bringing the total number to 1,265.

Mary Ramsay, head of immunisation at the UKHSA, said while their early data should be treated with caution, it indicates that "a few months after the second jab, there is a greater risk of catching the Omicron variant compared to Delta strain".

She added: "The data suggest this risk is significantly reduced following a booster vaccine, so I urge everyone to take up their booster when eligible."

Speaking to broadcasters, Gove said the Omicron variant is doubling every two to three days in England "and possibly even faster in Scotland".

He added that 30% of reported cases in London are the new variant, and warned that evidence suggests Omicron is "more likely" than past Covid variants to "potentially" lead to hospital admissions among the fully vaccinated.

Scotland's First Minister Nicola Sturgeon has warned of the possibility of a "tsunami of infections" from the new variant – and said she could not rule out more restrictions north of the border as a result.

But No 10 maintained that there were "no plans" to go further with measures in England, amid reports that proposals are being drawn up for a Plan C, featuring even tougher rules.

Gove said the current approach being taken is "proportionate", but acknowledged that "we absolutely do need to keep everything under review".

He said: "Action is absolutely required and, as new data comes in, we will consider what action we do require to take in the face of that data."

The Guardian reported that UK Health Secretary Sajid Javid had been given a presentation from the UKHSA earlier this week warning that even if Omicron leads to less serious disease than Delta, it still risks overwhelming the NHS with 5,000 people admitted to hospital a day.

It said the leaked advice said "stringent action" would be needed on or before December 18 if the variant's doubling time stays at 2.5 days, although the newspaper added that what such restrictions might entail were not set out other than to say measures that would bring the R number – representing the average number of people each Covid-19 positive person goes on to infect – below 1.

Professor Neil Ferguson, from Imperial College London, whose data was instrumental to the UK going into lockdown in March 2020, told The Guardian that projections suggest Omicron could "very substantially overwhelm the NHS, getting up to peak levels of admissions of 10,000 people per day".

He said such a figure could be reached "sometime in January" but added that it was based on assumptions around the variant's ability to get around existing protection, and the premise that it is similar to Delta in terms of the severity of disease it causes – something that is not yet known.

He said: "Even the best-case scenarios involve several-fold more admissions per day than we're getting at the moment – we are at about 700 right now."

New guidance expected to come into force from Wednesday will see care home residents allowed only three visitors and one essential care worker, as part of new measures to protect the sector from the spread of the new variant.

The Department of Health & Social Care said the move was "in order to balance the current Covid-19 risk and the need to keep people safe in line with clinical advice".

From Friday, in England the legal requirement to wear masks was extended to more indoor spaces including museums, galleries and community centres.

There will be a return to working from home guidance from Monday, and mandatory Covid passports for large venues from Wednesday.

The new regulations will be put to a debate and vote in the Commons next week – and with Labour's support they are certain to be approved despite the prospect of a large Conservative revolt.

Asked about the expected Tory rebellion, Gove said he is "confident" people will examine the proposals "seriously, soberly and thoughtfully", adding: "And I'm also confident people will conclude that, on balance, it is right to act."

By PA Reporters

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.